377 related articles for article (PubMed ID: 19379149)
1. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.
Slatinska J; Honsova E; Burgelova M; Slavcev A; Viklicky O
Ther Apher Dial; 2009 Apr; 13(2):108-12. PubMed ID: 19379149
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation.
Lehrich RW; Rocha PN; Reinsmoen N; Greenberg A; Butterly DW; Howell DN; Smith SR
Hum Immunol; 2005 Apr; 66(4):350-8. PubMed ID: 15866697
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection.
Rocha PN; Butterly DW; Greenberg A; Reddan DN; Tuttle-Newhall J; Collins BH; Kuo PC; Reinsmoen N; Fields T; Howell DN; Smith SR
Transplantation; 2003 May; 75(9):1490-5. PubMed ID: 12792502
[TBL] [Abstract][Full Text] [Related]
4. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
[TBL] [Abstract][Full Text] [Related]
5. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
6. Impact of rituximab therapy for treatment of acute humoral rejection.
Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
[TBL] [Abstract][Full Text] [Related]
7. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience.
Padmanabhan A; Ratner LE; Jhang JS; Duong JK; Markowitz GS; Vasilescu ER; Crew RJ; Schwartz J
Transplantation; 2009 Jun; 87(12):1889-96. PubMed ID: 19543070
[TBL] [Abstract][Full Text] [Related]
8. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features and treatment response of early acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience.
Larpparisuth N; Vongwiwatana A; Vareesangthip K; Cheunsuchon B; Parichatikanon P; Premasathian N
Transplant Proc; 2014; 46(2):474-6. PubMed ID: 24655992
[TBL] [Abstract][Full Text] [Related]
10. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute antibody-mediated rejection: a single-center experience.
Rodríguez Ferrero M; Rincón A; Bucalo L; Rementería A; Anaya F
Transplant Proc; 2010 Oct; 42(8):2848-50. PubMed ID: 20970547
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
[TBL] [Abstract][Full Text] [Related]
13. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
14. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
[TBL] [Abstract][Full Text] [Related]
15. Current approaches to treatment of antibody-mediated rejection.
Jordan SC; Vo AA; Tyan D; Nast CC; Toyoda M
Pediatr Transplant; 2005 Jun; 9(3):408-15. PubMed ID: 15910400
[TBL] [Abstract][Full Text] [Related]
16. The role of immunomodulation in ABO-incompatible adult liver transplant recipients.
Urbani L; Mazzoni A; Bianco I; Grazzini T; De Simone P; Catalano G; Montin U; Petruccelli S; Morelli L; Campani D; Pollina L; Biancofiore G; Bindi L; Tascini C; Menichetti F; Scatena F; Filipponi F
J Clin Apher; 2008; 23(2):55-62. PubMed ID: 18186527
[TBL] [Abstract][Full Text] [Related]
17. C4d-positive renal transplants: single-center clinical outcomes.
Ciszek M; Ptasińska AP; Durlik M; Paczek L
Clin Transpl; 2006; ():405-12. PubMed ID: 18365397
[TBL] [Abstract][Full Text] [Related]
18. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
19. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
[TBL] [Abstract][Full Text] [Related]
20. Multimodal therapy with combined plasmapheresis, photoapheresis, and intravenous immunoglobulin for acute antibody-mediated renal transplant rejection: a 2-year follow-up.
Lai Q; Pretagostini R; Gozzer M; Cinti P; Meo D; Vita F; Shafii Bafti M; Poli L; Novelli G; Rossi M; Girelli G; Berloco PB
Transplant Proc; 2011 May; 43(4):1039-41. PubMed ID: 21620047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
